Loading clinical trials...
Loading clinical trials...
A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100)
Conditions
Interventions
Chemotherapy + avelumab followed by avelumab + talazoparib
Chemotherapy followed by talazoparib maintenance
+1 more
Locations
72
United States
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States
Arizona Oncology Associates, PC - HAL
Scottsdale, Arizona, United States
Arizona Oncology Associates, PC - HAL
Tempe, Arizona, United States
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States
Start Date
July 19, 2018
Primary Completion Date
December 22, 2021
Completion Date
December 22, 2021
Last Updated
April 6, 2023
NCT06257264
NCT06964009
NCT06710548
NCT05005403
NCT06547840
NCT05080946
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions